Navigation Links
JDRF award supports study of potential target for blocking type 1 diabetes
Date:9/2/2009

NORFOLK, Va. Scientists at Eastern Virginia Medical School's Strelitz Diabetes Center have been awarded a two-year grant totaling $472,683 by the Juvenile Diabetes Research Foundation (JDRF).

The center's research team, led by Jerry Nadler, MD, professor and chair of internal medicine and director of the center, has been studying the role of an enzyme called 12- Lipoxygenase (12-LO) in damaging insulin-producing beta cells, a condition that leads to Type 1 Diabetes. "We have successfully identified a vital step in the development of Type 1 diabetes and we are hopeful that blocking this enzyme could hold the key to engineering breakthrough new treatments," Dr. Nadler said.

12-LO is a protein-based enzyme in beta cells that produces lipids. These lipids are highly pro-inflammatory and can lead to the death of beta cells. EVMS researchers have demonstrated that deletion of the gene that produces 12-LO in animal models prevents the development of Type 1 Diabetes at a rate of nearly 100 percent.

The group has now identified the particular form of 12-LO found in human insulin producing cells. And, while still preliminary, this research could help scientists develop a novel therapeutic approach to stop beta cells from being destroyed and to allow functional regeneration of beta cells in Type 1 Diabetes patients. Working with Ted Holman, PhD, a professor of chemistry and biochemistry at the University of California, Santa Cruz, the EVMS team hopes to use these findings to help develop a new drug.

"We are fortunate to be working with Dr. Holman, who has discovered some very promising compounds that can reduce 12-LO activity. Now, with the generosity and support of the JDRF, we can apply this technology to help prevent the destruction of beta cells and allow the regeneration of insulin-producing cells in Type 1 Diabetes," Dr. Nadler said.

"Dr. Nadler and his team have made amazing strides in our understanding of how lipoxygenase may contribute to the development of diabetes and opens the possibility of directly targeting this enzyme for treatment," Dr. Holman said. "Based on this important discovery, Dr. Nadler has already begun testing our lipoxygenase inhibitors in the hopes of generating new treatments for diabetes. His preliminary results are very promising and with his recent funding by the JDRF, we hope to make further progress."

"JDRF is thrilled to be supporting Dr. Nadler's work at EVMS as this research may represent an important step toward the development of a new therapeutic strategy for treating type 1 diabetes," said Patricia Kilian, PhD, director of regeneration at JDRF.

Often diagnosed in children and young adults, Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disorder associated with the destruction of insulin-producing beta cells. Without insulin, the body is unable to process sugars and starches leaving it unable to convert them into energy for movement, growth, repair and other functions.


'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-6074
Eastern Virginia Medical School
Source:Eurekalert

Related medicine news :

1. ING Awards $100,000 in Grants to Combat Childhood Obesity
2. Empire Blue Cross Blue Shield Awarded NCQAs Accreditation Status of Excellent
3. Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits
4. Vigilan Earns Honor in the 2009 Product & Technology Awards Program by Mature Market Resource Center
5. American Chemical Society Awards John R. Engen for Scientific Achievements
6. Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award
7. Nielsen Announces Final Entry Deadline Extension of September 10th for the First-Ever CLIO Healthcare Awards
8. Rhode Island Hospital awarded $11 million, 5-year renewal
9. Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntingtons Disease Community
10. Sundia Receives the Highest Growth Potential Award from Zhangjiang
11. The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... , ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon ... Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill has ... 40 Under 40 is an annual award that was started in 2003 to ...
(Date:9/21/2017)... CA (PRWEB) , ... September 21, 2017 , ... ... lunch and learn with Infinity Behavioral Health Services for professionals in the addiction ... a Commercial Payer Audit . , Insurance companies and state and federal ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent ... health departments have been awarded five-year accreditation status through the Public Health ... being served by a PHAB-accredited health department now extend to more than ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, ... the life-sciences industry for ensuring label quality and improving patient safety. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, Fumie and Kentaro ... 7th and 8th October at Miranda Kuo Gallery on Lower East Side, NYC. This ... Zen Kodo mat. Wanderlust , one of the largest US yoga online media ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
(Date:9/6/2017)... --  PDI , a leader in infection prevention products ... session focused on the role of chlorhexidine gluconate (CHG) ... 2017 Annual Scientific Meeting of the Association for Vascular ... Phoenix Convention Center in ... also feature PDI,s Prevantics® Device Swab as ...
Breaking Medicine Technology: